Julia García Prado
Dr. Julia G Prado holds a Bachelor's Degree in Biochemistry and a Ph.D. in Immunology with Honors from the Autonomous University of Barcelona. In 2006, she was awarded the prestigious Marie Sklodowska-Curie Fellowship to conduct her postdoctoral at the University of Oxford. In 2009, Dr. Prado returned to Spain and was awarded a highly competitive Miguel Servet Fellowship from the ISCIII, and in 2013 became the group leader of Virievac. Prado's laboratory research focuses on delineating the mechanism of "T cell immune exhaustion" as a significant barrier to HIV-1 cure and is actively involved in developing novel immunotherapies. Moreover, Dr. Prado has transferred her knowledge in antiviral immunity to characterize T-cell responses in SARS-CoV-2 infection and vaccination both for immune monitoring and understand protective immunity. Dr. Prado is currently the leader of the WP of immune monitoring in the European RBDCOV project and is a partner of the European ISIDORe project.
Dr. Prado's group has been continuously supported by competitive public calls and private contracts, building a solid network of R&D alliances and scientific collaborations. Dr. Prado has filed three patents, published 62 articles in Q1 and D1 international journals, accumulating an H-index of 26, and trained Ph.D., master, and graduate students from various national and international universities. In 2019, she joined the Germans Trias i Pujol Research Institute (IGTP) as Scientific Director, a position that combines with her role as a group leader at IrsiCaixa. She is an active member of the GESIDA-SEIMC group, the CIBERINFEC and a member of the scientific advisory board of EATRIS-Spain at the ISCIII.
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
Paediatric HIV slow-progression is associated with early CD8+ T-cell PD-1 expression and a stem-like phenotype.
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
Kinetics of humoral immune response over 17 months of COVID-19 pandemic in a large cohort of healthcare workers in Spain: the ProHEpiC-19 study.